Early Signals at ASCO 2026: How Do You Turn Next-Generation ADC Science Into Global Clinical Success?
Antibody-drug conjugates (ADCs) are transforming oncology, but scientific innovation alone isn't enough. As platforms become more sophisticated—with novel linker technologies, diversified payloads and increasingly targeted approaches—the challenge shifts from discovery to execution. How do sponsors successfully translate next-generation ADC science into global clinical development programs?
In this episode of Early Signals, Wael Harb, MD, sits down with Diana Chen, Vice President of Global Clinical Operations at MediLink Therapeutics, to discuss what it takes to operationalize innovation at scale. From building a rapidly growing ADC pipeline and managing global partnerships with leading biopharma companies to navigating cross-cultural clinical operations, Diana shares practical insights into the strategies shaping the next generation of oncology drug development.
Together, they explore how platform technologies like MediLink's TMALIN® linker are expanding the potential of ADCs, why global collaboration is becoming a competitive advantage and what operational excellence looks like in an increasingly complex development landscape.
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
Related Content
Looking for exclusive insight?
